Search - tctmd.com

Displaying 241 - 260 of 306

Sort: Relevancy | Date

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

News Conference News ESC 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

September 13, 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

September 01, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

News Industry News

Ortho Receives CE Mark for Enhanced VITROS® Immunodiagnostic Products NT-proBNP II Assay, an Aid in Diagnosing and Assessing Heart Failure

July 23, 2019

News Industry News

Nanowear Announces Clinical Launch of NanoSENSE, a Heart Failure Management and Alert Diagnostic Validation Study

July 22, 2019

News Industry News

Endotronix Enrolls First Patient in SIRONA II CE Mark Trial

July 15, 2019

Early Peek Hints at Safety and Utility of V-LAP Sensor for Monitoring Left Atrial Pressure

News Conference News ESC Heart Failure 2019

Early Peek Hints at Safety and Utility of V-LAP Sensor for Monitoring Left Atrial Pressure

May 29, 2019

News Industry News

Ortho's VITROS® High Sensitivity Troponin I Assay for the Diagnosis of Heart Attack Now CE Marked, Available in EU Countries

April 16, 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

News Industry News

Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

February 25, 2019

Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests

News Daily News

Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests

February 01, 2019

Artificial Intelligence From ECGs May ID Asymptomatic LV Dysfunction

News Daily News

Artificial Intelligence From ECGs May ID Asymptomatic LV Dysfunction

January 09, 2019

Takotsubo Syndrome Not Necessarily ‘Benign’ or Fleeting

News Daily News

Takotsubo Syndrome Not Necessarily ‘Benign’ or Fleeting

Yael L. Maxwell

January 07, 2019

Novel Interatrial Shunt Shows Promise at 1 Year in HF Patients With Reduced and Preserved EF

News Daily News

Novel Interatrial Shunt Shows Promise at 1 Year in HF Patients With Reduced and Preserved EF

November 02, 2018

TCTMD’s Top 10 Most Popular Stories for September 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

October 02, 2018

AHA Scientific Statement Aims to Raise Awareness of Chagas Disease and Risk for Cardiomyopathy

News Daily News

AHA Scientific Statement Aims to Raise Awareness of Chagas Disease and Risk for Cardiomyopathy

August 24, 2018

Diversity in Heart Failure Trials Still Falls Short

News Daily News

Diversity in Heart Failure Trials Still Falls Short

August 22, 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

August 20, 2018

Do PVADs and IABPs Offer Similar Survival in High-Risk PCI or Cardiogenic Shock?

News Daily News

Do PVADs and IABPs Offer Similar Survival in High-Risk PCI or Cardiogenic Shock?

July 30, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.